AnalysisNews

ADAG today

$1.52-$0.08 (-5.00%)close Nov 17, 2026

Trend

DailyDowntrend (confirmed)

4 hourStrong Bearish

1 hourStrong Bearish

15 minStrong Bearish

5 minStrong Bullish

Daily trend turns up above $3.10

Key levels

Resistance$2.24

Resistance$1.69

Support$1.30

Latest news & SEC filings

ProductNov 9, 2026Adagene finishes patient sign-up for mid-stage muzastotug study

ProductNov 9, 2026Adagene finishes enrolling patients in Phase 2 trial of muzastotug for MSS CRC lacking liver metastases

ProductOct 28, 2026Adagene begins Phase 1 dosing of muzastotug with Incyte's INCA33890

All ADAG news →

About Adagene

Adagene is a clinical-stage biopharmaceutical company that discovers and develops antibody-based cancer therapies. Its operations are conducted mainly through subsidiaries in China and the United States. The company develops novel antibody candidates using its proprietary platforms, with a focus on immuno-oncology treatments.

Based on the company's 20-F filed Apr 1, 2026.

Nasdaq · Healthcare

Adagene Inc. (ADAG)

$1.60-0.11 (-6.43%)
WATCHLISTGrade: ARisk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
1.872.132.402.661.60Oct 14Oct 22Oct 30Nov 9
High1.85
Low1.42
Open1.70
Volume944K
Avg Vol294K
VWAP1.52
30d High2.93
30d Low1.60
30d Chg-45.39%
See full chart with real-time data

What Is the Price Target for ADAG?

SEPT Low Target

$7.00

SEPT Mid Target

$9.00

SEPT High Target

$10.00

Analyst Consensus

$9.00

Current: $1.60Upside: +462.5%Confidence: 65%Method: Analyst Consensus

Is ADAG a Buy or Sell Right Now?

79
Investability Score
WATCHLIST12-18 months

Thesis

  • •Revenue growing 7332.8% YoY with ACCELERATING trend — accelerating momentum.

Test your own strategy on ADAG

Describe your strategy in plain words, then scan, alert, backtest and paper trade it on ADAG with SEPT’s own market data.

Start Free Trial →

Is ADAG Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

Analyst Consensus

Fair Value

$9.00

24

Moat Score

NONE

5/9

Piotroski Score

-2.8

Altman Z-Score

What Is Smart Money Doing with ADAG?

Insider Signal

NEUTRAL

1 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

MEDIUM

Signal: NEUTRAL

Recent Insider Activity

NameTitleTypeSharesValueDate
Tam Man Kindirector officerBuy2,000$6KSep 23, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See Smart Money Data →

ADAG Growth Story

Revenue YoY

7332.8%

3yr Revenue CAGR

-6.2%

EPS Growth YoY

49.15%

FCF Growth YoY

47.3%

Revenue Trend

ACCELERATING

Dark Pool Trades for ADAG

PREVIEW

Recent off-exchange (dark pool) prints for ADAG: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.

TimePriceSizeValueSide
21:00:00$1.603,315$$5KMIDPOINT
20:59:37$1.611,100$$2KBUY
20:45:31$1.451,600$$2KSELL
20:40:52$1.461,400$$2KSELL
20:40:12$1.491,200$$2KSELL

5 dark pool trades shown · $$13K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Adagene Inc. (ADAG) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...

Sign Up Free — Download AI Report PDF →

Your strategy, tested before real money.

Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.

Try SEPT Free for 7 Days →
What is dark pool trading?How to read options flowGEX explainedSmart money trackingAI stock analysisEarn money on SEPT

About SEPT Investing

SEPT Investing tracks 13,000+ stocks with live charts, trend and key-level tracking, dark pool and options flow, insider and congress trades, SEC filings and news alerts.

Disclaimer: This page is for informational purposes only. It does not constitute financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.

ADAG — frequently asked questions

What is ADAG stock price today?

Adagene Inc. (ADAG) is at $1.52, down 5.00% (-$0.08) at the Nov 17, 2026 close.

Why is ADAG stock moving today?

Latest ADAG news — Nov 9, 2026: Adagene finishes patient sign-up for mid-stage muzastotug study · Nov 9, 2026: Adagene finishes enrolling patients in Phase 2 trial of muzastotug for MSS CRC lacking liver metastases

What is the ADAG price target?

The average analyst price target for ADAG is $9.00, ranging from $7 to $10, based on 3 analysts.

What do analysts rate ADAG?

Analyst ratings for ADAG: 1 Buy, 2 Hold, 0 Sell — consensus Hold.

Did ADAG beat earnings?

ADAG last reported on Aug 12, 2026: EPS -$0.23 vs -$0.22 expected — a miss of 4.5%.

What are ADAG support and resistance levels?

Support: $1.30. Resistance: $1.69, $2.24, $2.78.

What are insiders doing with ADAG?

Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.

What is the latest news on ADAG?

Nov 9, 2026: Adagene finishes patient sign-up for mid-stage muzastotug study · Nov 9, 2026: Adagene finishes enrolling patients in Phase 2 trial of muzastotug for MSS CRC lacking liver metastases · Oct 28, 2026: Adagene begins Phase 1 dosing of muzastotug with Incyte's INCA33890